EAN 2026 | Incorporating broad rim lesions as a biomarker of MS into clinical practice: barriers and next steps
Joost Smolders, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, discusses the challenges of incorporating broad rim lesions as a biomarker of multiple sclerosis (MS) into clinical practice. Dr Smolders highlights the importance of identifying lesion types through accessible detection methods to capture biological variations and guide therapy decisions. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think most importantly one of the limitations is that we identified the broad rim lesion on postmortem tissue right so then it’s not really that helpful for our patients during life and I think it’s important that thanks to the work of Professor Airas we are now able to image broadness of the myelinating rim on PET imaging. But also PET imaging is not performed in regular clinical practice...
I think most importantly one of the limitations is that we identified the broad rim lesion on postmortem tissue right so then it’s not really that helpful for our patients during life and I think it’s important that thanks to the work of Professor Airas we are now able to image broadness of the myelinating rim on PET imaging. But also PET imaging is not performed in regular clinical practice. So I think a real game changer will be if we can identify these lesion types on regular MRI scans as we currently do in clinical practice or when we find soluble biomarkers that could predict the presence of broad lesions in our patients. I think this will be most important to really capture this variation in biology represented by broad rim lesions in different cohorts of people with MS and then also apply this knowledge in trying to understand what it means for the disease itself but also for targeting with MS therapies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
